1Zheng-Xu Wang~1 Gui-Fang Hu~1 Hong-Yang Wang~2 Meng-Chao Wu~2 1 Department of General Surgery,Chinese PEA General Hospital of Lanzhou Military Command,Lanzhou 730050,Gansu Province,China2 Eastern Hepatobilliary Surgical Hospital,Second Military Medical University,Shanghai 200438,China.Expression of liver cancer associated gene HCCA3[J].World Journal of Gastroenterology,2001,7(6):821-825. 被引量：9
2Yi-Long Xue~1 Shi-Feng Zhao~1 Yun-Luo~1 Xin-Jian Li~1 Zhong-Ping Duan~2 Xiao-Ping Chen~1 Wen-Ge Li~1 Xiao-Qiang Huang~1 Yan-Ling Li~1 Xin-Cui~1 Da-Guang Zhong~1 Zuo-Yun Zhang~1 Zhi-Qiang Huang~1 1 Chinese PLA General Hospital,Beijing 100853,China2 Beijing You-An Hospital,Beijing 100054,China.TECA hybrid artificial liver support system in treatment of acute liver failure[J].World Journal of Gastroenterology,2001,7(6):826-829. 被引量：16
4Zhang D K, Ngan H Y, Cheng R Y, et al. Clinical significance of telomer- ase activation and telomeric restriction fragment(TRF) in cervical cancer. Eur J Cancer,1999;35(1): 154-160.
5Shroyer K R,Thompson L C, Enomoto T, et al. Telomerase expression in normal epithelium, reactive atypia, squamous dysplasia and squamous cell car- cinoma of the uterine cervix. Am J Clin Pathol,1998;109(2): 153 - 162.
6Nagai N,Oshita T,Murakami J,et al. Semiquantitative analysis of telom- erase activitv in cervical cancer and precancerous lesions. Oncol Rep, 1999 ;6 (2): 325-328.
7Collado M, Blasco MA, Serrano M. Cellular senescence in cancer and aging. Ce11,2007 ;130(2) : 223 -233.
8Hornsb PJ. Senescence as an anticancer mechanism . Clinic oncology, 2007;25(14): 1852-1857.
9van Steensel B, de Lange T. Control of telomere length by the human te- lomeric protein TRF1 [ J]. Nature, 1997,385 ( 6618 ) :740.
10Smogorzewska A, van Steensel B, Bianchi A, et al. Control of human te- lomere length by TRF1 and TRF2 [J]. Mol Cell Biology ,2000,20( 5 ) : 1659.
